Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;6(1):e001136.
doi: 10.1136/rmdopen-2019-001136.

Peripheral spondyloarthritis: a neglected entity-state of the art

Philippe Carron #  1   2 , Ann-Sophie De Craemer #  3   2 , Filip Van den Bosch  3   2
Affiliations
Review

Peripheral spondyloarthritis: a neglected entity-state of the art

Philippe Carron et al. RMD Open. 2020 May.

Abstract

Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or dactylitis predominate the clinical presentation. Although formal classification criteria for pSpA have been introduced in 2011, only a minority of epidemiological and clinical studies addressed this clinical entity as a separate disease. Moreover, research on outcome measures and treatment modalities in pSpA has been mainly focused on PsA. Subsequently, all biological treatments are off-label in patients with non-psoriatic pSpA. Its neglected status has important implications for clinical practice since the emerging group of early-diagnosed non-psoriatic pSpA patients remains poorly characterised and lacks specific treatment recommendations. This review summarises what is currently known regarding pSpA in terms of epidemiology, clinical presentation, diagnosis and therapeutic approach.

Keywords: Ankylosing spondylitis; Anti-TNF; Magnetic resonance imaging; Rheumatoid arthritis; Spondyloarthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127–37.10.1016/S0140-6736(11)60071-8 - DOI - PubMed
    1. Moll JM, Haslock I, Macrae IF, et al. . Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine 1974;53:343–64. 10.1097/00005792-197409000-00002 - DOI - PubMed
    1. Rudwaleit M, Van der Heijde D, Landewé R, et al. . The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.10.1136/ard.2009.108233 - DOI - PubMed
    1. Rudwaleit M, van der Heijde D, Landewe R, et al. . The assessment of Spondyloarthritis International Society Classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.10.1136/ard.2010.133645 - DOI - PubMed
    1. Varkas G, Cypers H, Van Praet L, et al. . OP0263 first results from “be-giant”: baseline characteristics of an early Spondyloarthritis Cohort. Ann Rheum Dis 2014;73:161–161.10.1136/annrheumdis-2014-eular.4951 - DOI - PubMed

MeSH terms